News

Kathleen Sebelius, Secretary of the US Department of Human Health and Services (HHS), has announced that the US will provide 420,000 treatment courses of Tamiflu to the Pan-American

Lundbeck announces positive headline results from a dose finding clinical trial with the compound Lu AA24530. It is intended for the treatment of major depressive disorder (MDD). The

Genentech has announced that the phase-III study of Bravo showed that Lucentis (ranibizumab injection) improved vision in patients with macular edema due to branch retinal vein occlusion. Lucentis

National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI) and National Institutes of Health have reported that Lixte’s novel compound, LB-1.2, enhances the

Eisai is currently focusing on three clinical development programs related to Aricept (donepezil hydrochloride), for Alzheimer’s disease. Eisai has completed a phase-III study of 23mg donepezil sustained release

Oncolytics has completed the patient enrolment in the phase II component of a phase I/II UK trial of Reolysin combined with paclitaxel/carboplatin. It is intended for patients with

Connectyx has entered into an agreement with Healthy Directions, to promote and sell Connectyx’s MedFlash products through its various distribution channels. Tom Callahan, Senior Vice President of Healthy

Winner Medical has signed an agreement with a consumer products company in China, to provide PurCotton rolls. Under the agreement, Winner Medical will provide PurCotton raw materials, which

Johnson & Johnson (J&J) and Elan have signed an agreement whereby J&J (through a newly formed company) will acquire all the assets and rights of Elan related to